mitogen-activated protein kinase kinase kinase 21Genealiases: MLK4 · dJ862P8.3
Q-omics provides the consensus-scored MAP3K21 profile across patient tissues and cancer cell-line models. MAP3K21 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MAP3K21 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, MAP3K21 RNA expression shows 21,518 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KICH, and LSCC as cancer lineages where MAP3K21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAP3K21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAP3K21 survival associations across molecular data types. MAP3K21 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAP3K21 RNA expression–survival associations across cancer types. High MAP3K21 expression shows unfavorable associations in UVM, KIRP, LIHC and CESC, but favorable associations in SKCM and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MAP3K21 RNA expression.
This table summarizes MAP3K21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for MAP3K21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAP3K21 shows lower tumor expression in KICH and KIRC and higher tumor expression in HNSC, BLCA, COAD and UCEC. The KICH box plot shows higher MAP3K21 RNA expression in normal versus tumor tissue (log2 FC = −1.592, t-test p < 0.001).
This table shows molecular features associated with MAP3K21 in patient tissues and cancer cell lines. In patient samples, MAP3K21 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MAP3K21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
